Latigo Biotherapeutics (LTGO) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Latigo Biotherapeutics is the larger company by market cap ($981.9 million vs $874.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTGO | MLTX |
|---|---|---|
| Share price | $14.81 | $10.28 |
| Market cap | $981.89M | $874.90M |
| 1-day change | -4.57% | -4.55% |
| YTD return | — | -18.29% |
| 1-year return | — | +16.06% |
| 5-year return | — | +8.57% |
| EPS (TTM) | $-2.52 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.93 | $23.29 |
| 52-week low | $14.60 | $8.80 |
| Distance from 52-week high | -42.88% | -55.86% |
| Analyst consensus | none | buy |
| Avg. price target upside | +252.80% | +177.63% |
| Average volume | 394.20K | 1.44M |
| Shares outstanding | 66.30M | 85.11M |
| Employees | 66 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
LTGO vs MLTX FAQ
Which is bigger, Latigo Biotherapeutics or MoonLake Immunotherapeutics?
Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $981.89M compared with $874.90M for MoonLake Immunotherapeutics (MLTX).
Are Latigo Biotherapeutics and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.